Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Wuchner

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Pharmaceutical Sciences|March 27, 2026
Industry guidance on container closure integrity strategies for difficult-to-test parenteral products (DTPs)Klaus Wuchner, David Riesop, Carine Huon, et al.
PDA Journal of Pharmaceutical Science and Technology|October 30, 2016
Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical IndustryHelen Brown, Hanns-Christian Mahler, James Mellman, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 19, 2023
Industry perspective on a holistic container closure integrity approach to parenteral combination productsKlaus Wuchner, Helen C Brown, Fabiana Canal, et al.
Journal of Pharmaceutical Sciences|October 6, 2023
Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle VisibilityMaryam Mazaheri, Miguel Saggu, Klaus Wuchner, et al.
Journal of Pharmaceutical Sciences|January 19, 2026
Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studiesKlaus Wuchner, Felix Nikels, Patrick Garidel, et al.
Journal of Pharmaceutical Sciences|October 25, 2019
A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein ProductsMario Hubert, Dennis T Yang, Stanley C Kwok, et al.
AAPS Pharmscitech|December 16, 2022
An Interlaboratory Study to Identify Potential Visible Protein-Like Particle StandardsSrivalli N Telikepalli, Michael J Carrier, Dean C Ripple, et al.
Journal of Pharmaceutical Sciences|February 22, 2022
Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of PolysorbatesKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|August 24, 2022
Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the FutureKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|April 3, 2015
Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and StrategyLinda O Narhi, Vincent Corvari, Dean C Ripple, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Pharmaceutical Sciences|March 27, 2026
Industry guidance on container closure integrity strategies for difficult-to-test parenteral products (DTPs)Klaus Wuchner, David Riesop, Carine Huon, et al.
PDA Journal of Pharmaceutical Science and Technology|October 30, 2016
Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical IndustryHelen Brown, Hanns-Christian Mahler, James Mellman, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 19, 2023
Industry perspective on a holistic container closure integrity approach to parenteral combination productsKlaus Wuchner, Helen C Brown, Fabiana Canal, et al.
Journal of Pharmaceutical Sciences|October 6, 2023
Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle VisibilityMaryam Mazaheri, Miguel Saggu, Klaus Wuchner, et al.
Journal of Pharmaceutical Sciences|January 19, 2026
Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studiesKlaus Wuchner, Felix Nikels, Patrick Garidel, et al.
Journal of Pharmaceutical Sciences|October 25, 2019
A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein ProductsMario Hubert, Dennis T Yang, Stanley C Kwok, et al.
AAPS Pharmscitech|December 16, 2022
An Interlaboratory Study to Identify Potential Visible Protein-Like Particle StandardsSrivalli N Telikepalli, Michael J Carrier, Dean C Ripple, et al.
Journal of Pharmaceutical Sciences|February 22, 2022
Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of PolysorbatesKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|August 24, 2022
Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the FutureKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|April 3, 2015
Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and StrategyLinda O Narhi, Vincent Corvari, Dean C Ripple, et al.
Pageof 4